Intersite variability of CSF Alzheimer's disease biomarkers in clinical setting

Alzheimer's and Dementia

Volumn 9, Issue 4, 2013, Pages 406-413

  Dumurgier, Julien ^a   Vercruysse, Olivier ^b,c   Paquet, Claire ^a,d   Bombois, Stephanie ^b   Chaulet, Chloe ^e   Laplanche, Jean Louis ^a   Peoc'h, Katell ^a   Schraen, Susanna ^c   Pasquier, Florence ^b   Touchon, Jacques ^e   Hugon, Jacques ^a,d   Lehmann, Sylvain ^e   Gabelle, Audrey ^e  

^a HÔPITAL FERNAND WIDAL   (France)

^b LILLE UNIVERSITY HOSPITAL   (France)

^c UNIV LILLE   (France)

^d INSTITUT DU FER À MOULIN   (France)

^e UNIV MONTPELLIER   (France)

Author keywords

Alzheimer's disease; Amyloid b; Biomarkers; Cerebrospinal fluid; Tau; Variability

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; PROTEIN PTAU 181; TAU PROTEIN; UNCLASSIFIED DRUG;

AGED; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID; FEMALE; HUMAN; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; PRIORITY JOURNAL;

EID: 84882456499     PISSN: 15525260     EISSN: 15525279     Source Type: Journal    
DOI: 10.1016/j.jalz.2012.06.006     Document Type: Article

References (35)

1. Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L, Ganguli M, et al. Global prevalence of dementia: A Delphi consensus study. Lancet 2005;366:2112-7.
2. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDAWork Group under the auspices of the Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-44.
3. Knopman DS, DeKosky ST, Cummings JL, Chui H, Corey-Bloom J, Relkin N, et al. Practice parameter: Diagnosis of dementia (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001; 56:1143-53.
4. Shaw LM, Korecka M, Clark CM, Lee VM, Trojanowski JQ. Biomarkers of neurodegeneration for diagnosis and monitoring therapeutics. Nat Rev 2007;6:295-303.
5. Petersen RC. Early diagnosis of Alzheimer's disease: Is MCI too late? Current Alzheimer Res 2009;6:324-30.
6. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, et al. The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011;7:263-9.
7. Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol 2010; 6:131-44.
8. Blennow K, Zetterberg H. Cerebrospinal fluid biomarkers for Alzheimer's disease. J Alzheimers Dis 2009;18:413-7.
9. Tapiola T, Alafuzoff I, Herukka SK, Parkkinen L, Hartikainen P, Soininen H, et al. Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Arch Neurol 2009;66:382-9.
10. Dumurgier J, Paquet C, Benisty S, Kiffel C, Lidy C, Mouton-Liger F, et al. Inverse association between CSFAbeta 42 levels and years of education in mild form of Alzheimer's disease: The cognitive reserve theory. Neurobiol Dis 2010;40:456-9.
11. Dumurgier J, Paquet C, Peoc'h K, Lapalus P, Mouton-Liger F, Benisty S, et al. CSF Abeta levels and glucose metabolism in Alzheimer's disease. J Alzheimers Dis 2011;27:845-51.
12. Johansson P, Mattsson N, Hansson O, Wallin A, Johansson JO, Andreasson U, et al. Cerebrospinal fluid biomarkers for Alzheimer's disease: Diagnostic performance in a homogeneous mono-center population. J Alzheimers Dis 2011;24:537-46.
13. Blennow K. Cerebrospinal fluid protein biomarkers for Alzheimer's disease. NeuroRx 2004;1:213-25.
14. Mattsson N, Zetterberg H, Hansson O, Andreasen N, Parnetti L, Jonsson M, et al. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA 2009;302:385-93.
15. Visser PJ, Verhey F, Knol DL, Scheltens P, Wahlund LO, Freund-Levi Y, et al. Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: A prospective cohort study. Lancet Neurol 2009;8:619-27.
16. Parnetti L, Chiasserini D. Role of CSF biomarkers in the diagnosis of prodromal Alzheimer's disease. Biomarkers Med 2011;5:479-84.
17. Lewczuk P, Beck G, Ganslandt O, Esselmann H, Deisenhammer F, Regeniter A, et al. International quality control survey of neurochemical dementia diagnostics. Neurosci Lett 2006;409:1-4.
18. Mattsson N, Andreasson U, Persson S, Arai H, Batish SD, Bernardini S, et al. The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers. Alzheimers Dement 2011;7:386-95.
19. Verwey NA, van der Flier WM, Blennow K, Clark C, Sokolow S, De Deyn PP, et al. Aworldwide multicentre comparison of assays for cerebrospinal fluid biomarkers in Alzheimer's disease. Ann Clin Biochem 2009;46:235-40.
20. EwersM, Schmitz S,HanssonO,WalshC, FitzpatrickA, BennettD, et al. Body mass index is associated with biological CSFmarkers of core brain pathology of Alzheimer's disease. Neurobiol Aging 2012;33:e1-2.
21. Petersen RC, Trojanowski JQ. Use of Alzheimer disease biomarkers: Potentially yes for clinical trials but not yet for clinical practice. JAMA 2009;302:436-7.
22. MattssonN, ZetterbergH, BlennowK. Lessons frommulticenter studies on CSF biomarkers for Alzheimer's disease. Int JAlzheimers Dis 2010.
23. Perret-Liaudet A, Pelpel M, Tholance Y, Dumont B, Vanderstichele H, Zorzi W, et al. Cerebrospinal fluid collection tubes: A critical issue for Alzheimer disease diagnosis. Clin Chem 2012; 58:787-9.
24. Bateman RJ, Wen G, Morris JC, Holtzman DM. Fluctuations of CSF amyloid-beta levels: Implications for a diagnostic and therapeutic biomarker. Neurology 2007;68:666-9.
25. Shaw LM, Vanderstichele H, Knapik-Czajka M, Figurski M, Coart E, Blennow K, et al. Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI. Acta Neuropathol 2011;121:597-609.
26. Vanderstichele H, Bibl M, Engelborghs S, Le Bastard N, Lewczuk P, Molinuevo JL, et al. Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: A consensus paper from the Alzheimer's Biomarkers Standardization Initiative. Alzheimers Dement 2012;8:65-73.
27. Kester MI, Boelaarts L, Bouwman FH, Vogels RL, Groot ER, van Elk EJ, et al. Diagnostic impact of CSF biomarkers in a local hospital memory clinic. Dement Geriatr Cogn Disord 2010; 29:491-7.
28. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: Clinical characterization and outcome. Arch Neurol 1999;56:303-8.
29. Slats D, Claassen JA, Spies PE, Borm G, Besse KT, Aalst WV, et al. Hourly variability of cerebrospinal fluid biomarkers in Alzheimer's disease subjects and healthy older volunteers. Neurobiol Aging 2012;33:e831-9.
30. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986;1:307-10.
31. Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC, et al.Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol 2009;65:403-13.
32. Buerger K, Frisoni G, Uspenskaya O, Ewers M, Zetterberg H, Geroldi C, et al. Validation of Alzheimer's disease CSF and plasma biological markers: The multicentre reliability study of the pilot European Alzheimer's Disease Neuroimaging Initiative (E-ADNI). Exp Gerontol 2009;44:579-85.
33. Mattsson N, Blennow K, Zetterberg H. Inter-laboratory variation in cerebrospinal fluid biomarkers for Alzheimer's disease: United we stand, divided we fall. Clin Chem Lab Med 2010;48:603-7.
34. Spies PE, Slats D, Sjogren JM, Kremer BP, Verhey FR, Rikkert MG, et al. The cerebrospinal fluid amyloid beta42/40 ratio in the differentiation of Alzheimer's disease from non-Alzheimer's dementia. Curr Alzheimer Res 2010;7:470-6.
35. Mouton-Liger F, Paquet C, Dumurgier J, Lapalus P, Gray F, Laplanche JL, et al. Increased cerebrospinal fluid levels of doublestranded RNA-dependant protein kinase in Alzheimer's disease. Biol Psychiatry 2012;71:829-35.